CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Warfarin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01263119
NCT01263119Phase 1Completed
CompareCT.gov

Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects

Eli Lilly and Company·interventional·Posted Dec 20, 2010·Updated Jan 22, 2019

In Brief

A Phase 1 clinical trial evaluating Warfarin and LY2216684 for Major Depressive Disorder. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how warfarin might affect LY2216684 and how giving LY2216684 might affect warfarin in the body. Information about any side effects that may occur will also be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2010
Enrollment StartDec 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.5 years ago

Interventions

Warfarindrug

10-mg warfarin oral dose

LY2216684drug

18-mg LY2216684 oral dose